Skip to main content
×
Home

Antibody-based therapy of leukaemia

  • John C. Morris (a1) and Thomas A. Waldmann (a1)
Abstract

Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies – the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab – are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia. Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia. Here, we discuss how these new antibodies have been engineered to reduce immunogenicity and improve antibody targeting and binding. Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.

Copyright
Corresponding author
*Corresponding author: John C. Morris, Co-Director Clinical Trials, Metabolism Branch, Center for Cancer Research National Cancer Institute, Mark O. Hatfield Clinical Research Center, Room 4-5330, 10 Center Drive, Bethesda, Maryland 20892-1457, USA. Tel: +1 301 402 2912; Fax: +1 301 402 1001; E-mail: jmorris@mail.nih.gov
References
Hide All
1Ehrlich P. (1899–1900) Croonian Lecture: On immunity with special reference to cell life Proceedings of the Royal Society of London 66, 424-448
2Köhler G. and Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497
3Byrd J.C. et al. (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology 19, 2153-2164
4Hagberg H. (1999) Chimeric monoclonal anti-CD20 antibody (rituximab) – an effective treatment for a patient with relapsing hairy cell leukaemia. Medical Oncology 16, 221-222
5Swann P.G. et al. (2008) Considerations for the development of therapeutic monoclonal antibodies. Current Opinion in Immunology 20, 493-499
6Liu X.Y., Pop L.M. and Vitetta E.S. (2008) Engineering therapeutic monoclonal antibodies. Immunological Reviews 222, 9-27
7Nissim A. and Chernajovsky Y. (2008) Historical development of monoclonal antibody therapeutics. In Handbook of Experimental Pharmacology: Therapeutic Antibodies. (Chernajovsky Y. and Nissim A., eds.) 181, pp. 3-18, Springer
8Lonberg N. (2008) Human monoclonal antibodies from transgenic mice. In Handbook of Experimental Pharmacology: Therapeutic Antibodies, (Chernajovsky Y. and Nissim A., eds.) 181, pp. 69-97, Springer
9Veri M.C. et al. (2007) Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121, 392-404
10Perz J.Topaly J., Fruehauf S., Hensel M., and Ho A.D. (2002) Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma 43, 149-151
11Coiffier B. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 346, 235-242
12Sehn L.H. et al. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology 23, 5027-5033
13Marcus R. et al. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology 26, 4579-4586
14Kantarjian H. et al. (2008) Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113 (Suppl.), 1933-1952
15Freeman S.D., Kelm S., Barber E.K., and Crocker P.R. (1995) Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85, 2005-2012
16Crocker P.R. and Redelinghuys P. (2008) Siglecs as positive and negative regulators of the immune system. Biochemical Society Transactions 36, 1467-1471
17Dinndorf P.A., Andrews R.G., Benjamin D., Ridgway D., Wolff L. and Bernstein I.D. (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67, 1048-1053
18Hamann P.R. et al. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chemistry 13, 40-66
19Zein N., Sinha A.M., McGahren W.J. and Ellestad G.A. (1988) Calicheamicin gamma 1: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240, 1198-1201
20van Der Velden V.H. et al. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97, 3197-3204
21Naito K. et al. (2000) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14, 1436-1443
22Dowell J.A., Korth-Bradley J., Liu H., King S.P. and Berger M.S. (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. Journal of Clinical Pharmacology 41, 1206-1214
23Sievers E.L. et al. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93, 3678-3684
24Larson R.A. et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Cancer 104, 1442-1452
25Kell W.J. et al. (2003) A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102, 4277-4283
26 Tsimberidou, A.M. et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology 52, 449-452
27Amadori S. et al. (2004) Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89, 950-956
28Nabhan C. et al. (2005) Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leukemia Research 29, 53-57
29Chevallier P. et al. (2005) Administration of Mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research 29, 1003-1007
30Chevallier P. et al. (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Journal of Clinical Oncology 26, 5192-5197
31Aribi A. et al. (2007) Combination therapy with arsenic trioxide, all-trans-retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109, 1355-1359
32Linenberger M.L. et al. (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98, 988-994
33van Der Velden V.H. et al. (2004) High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18, 983-988
34Chevallier P. et al. (2008) Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. British Journal of Haematology 143, 744-746
35Feldman E.J. et al. (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of Clinical Oncology 23, 4110-4116
36Schwartz M.A. et al. (1993) Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Journal of Clinical Oncology 11, 294-303
37Sgouros G. et al. (1999) Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. Journal of Nuclear Medicine 40, 1935-1946
38Mustelin T., Vang T. and Bottini N. (2005) Protein tyrosine phosphatases and the immune response. Nature Reviews Immunology 5, 43-57
39Matthews D.C. et al. (1999) Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94, 1237-1247
40Pagel J.M. et al. (2006) 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107, 2184-2191
41Stocks S.C., Ruchaud-Sparagano M.H., Kerr M.A., Grunert F., Haslett C. and Dransfield I. (1996) CD66: role in the regulation of neutrophil effector function. European Journal of Immunology 26, 2924-2932
42Bunjes D. et al. (2001) Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98, 565-572
43Ringhoffer M. et al. (2005) 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. British Journal of Haematology 130, 604-613
44Zenz T. et al. (2006) Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. Haematologica 91, 285-286
45Buchmann I. et al. (2003) A comparison of the biodistribution and biokinetics of (99 m)Tc-anti-CD66 mAb BW 250/183 and (99 m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy. European Journal of Nuclear Medicine and Molecular Imaging 30, 667-673
46Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine 12, 1167-1174
47Graf M., Hecht K., Reif S., Pelka-Fleischer R., Pfister K. and Schmetzer H. (2004) Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. European Journal of Haematology 72, 89-106
48Misaghian N. et al. (2009) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23, 25-42
49Du X., Ho M. and Pastan I. (2007) New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. Journal of Immunotherapy 30, 607-613
50Nadler L.M., Ritz J., Hardy R., Pesando J.M., Schlossman S.F. and Stashenko P. (1981) A unique cell surface antigen identifying lymphoid malignancies of B cell origin. The Journal of Clinical Investigation 67, 134-140
51Riley J.K. and Sliwkowski M.X. (2000) CD20: a gene in search of a function. Seminars in Oncology 27 (Suppl. 12), 17-24
52Press O.W., Howell-Clark J., Anderson S. and Bernstein I. (1994) Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83, 1390-1397
53Reff M.E. et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445
54Smith M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359-7368
55Stolz C. et al. (2008) Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 112, 3312-3321
56Clynes R.A., Towers T.L., Presta L.G. and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nature Mediane 6, 443-446
57Cartron G. et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene. Blood 99, 754-758
58Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D. and Byrd J.C. (2004) Fc gamma RIIIα and Fc gamma RIIα polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103, 1472-1474
59Byrd J.C., et al. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99, 1038-1043
60Maloney D.G. et al. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466
61Maloney D.G. et al. (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology 15, 3266-3274
62Berinstein N.L. et al. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology 9, 995-1001
63McLaughlin P. et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16, 2825-2833
64Piro L.D. et al. (1998) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology 10, 655-661
65Nguyen D.T., Amess J.A., Doughty H., Hendry L. and Diamond L.W. (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. European Journal Haematology 62, 76-82
66Ladetto M., Bergui L., Ricca I., Campana S., Pileri A. and Tarella C. (2000) Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Medical Oncology 17, 203-210
67Hainsworth J.D. et al. (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology 21, 1746-1751
68Foran J.M. et al. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology 18, 317-324
69O'Brien S.M. et al. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology 19, 2165-2170
70Perz J., Topaly J., Fruehauf S., Hensel M. and Ho A.D. (2002) Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leukmia and Lymphoma 43, 149-151
71Byrd J.C. et al. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101, 6-14
72Byrd J.C. et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53
73Lamanna N. et al. (2009) Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. Journal of Clinical Oncology 27, 491-497
74Foon K.A. et al. (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 27, 498-503
75Lauria F. et al. (2001) Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86, 1046-1050
76Nieva J., Bethel K. and Saven A. (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102, 810-813
77Winkler U., Jensen M., Manzke O., Schulz H., Diehl V. and Engert A. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94, 2217-2224
78Robak T. (2008) Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Current Opinion in Molecular Therapeutics 10, 294-309
79Teeling J.L. et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 104, 1793-1800
80Hagenbeek A. et al. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111, 5486-5495
81Coiffier B. et al. (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111, 1094-1100
82Osterborg A. et al. (2008) Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial. Blood 112, 328 [Abstract]
83Liu A.Y., Robinson R.R., Murray E.D. Jr., Ledbetter J.A., Hellström I. and Hellström K.E. (1987) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. Journal of Immunology 139, 3521-3526
84Morschhauser F. et al. (2007) Interim results of a phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma. Blood 110, 645 [Abstract]
85Stein R. et al. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clinical Cancer Research 10, 2868-2878
86Morschhauser F. et al. (2007) Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results. J Clin Oncol, ASCO Annual Meeting Proceedings 25, 8032 [Abstract]
87Dorshkind K. and Montecino-Rodriguez E. (2007) Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nature Reviews Immunology 7, 213-219
88Ball E.D. et al. (1991) Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 77, 2242-2250
89Bradstock K., Matthews J., Benson E., Page F. and Bishop J. (1994) Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 84, 1220-1225
90Carter R.H. and Fearon D.T. (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-107
91Bobbitt K.B. and Justement L.B. (2000) Regulation of MHC class II signal transduction by the B cell coreceptors CD19 and CD22. Journal of Immunology 165, 5588-5596
92Horton H.M. et al. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Research 68, 8049-8057
93Zalevsky J. et al. (2009) The impact of Fc engineering on an anti-CD19 antibody: increased Fc-gamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113, 3735-3743
94Khouri I.F. et al. (1994) Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. Journal of Clinical Oncology 12, 748-758
95Paulus U., Schmitz N., Viehmann K., von Neuhoff N. and Dreger P. (1997) Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant 20, 415-420
96Dreger P. et al. (2000) A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Experimental Hematology 28, 1187-1196
97Szatrowski T.P. et al. (2003) Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer 97, 1471-1480
98Walker J.A. and Smith K.G. (2008) CD22: An inhibitory enigma. Immunology 123, 314-325
99Leung S.O. et al. (1994) Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma. Hybridoma 13, 469-476
100Carnahan J. et al. (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Molecular Immunology 44, 1331-1341
101Leonard J.P. et al. (2004) Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10, 5327-5334
102Micallef I.N. et al. (2006) A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107, 2826-2832
103Raetz E.A. et al. (2008) Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. Journal of Clinical Oncology 26, 3756-3762
104Kreitman R.J. et al. (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Journal of Clinical Oncology 23, 6719-6729
105Kreitman R.J. et al. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New England Journal of Medicine 345, 241-247
106Bang S., Nagata S., Onda M., Kreitman R.J. and Pastan I. (2005) HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clinical Cancer Research 11, 1545-1550
107DiJoseph J.F. et al. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103, 1807-1814
108DiJoseph J.F., Dougher M.M., Armellino D.C., Evans D.Y. and Damle N.K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21, 2240-2245
109Delespesse G. et al. (1991) Expression, structure, and function of the CD23 antigen. Advances in Immunology 49, 149-191
110Bonnefoy J.Y. et al. (1997) Structure and functions of CD23. International Reviews of Immunology 16, 113-128
111Reichert J.M. (2004) Technology evaluation: lumiliximab, Biogen Idec. Current Opinion in Molecular Therapeutics 6, 675-683
112Pathan N.I., Chu P., Hariharan K., Cheney C., Molina A. and Byrd J. (2008) Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111, 1594-1602
113Byrd J.C. et al. (2007) Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research 13, 4448-4455
114Treumann A., Lifely M.R., Schneider P. and Ferguson M.A. (1995) Primary structure of CD52. Journal of Biological Chemistry 270, 6088-6099
115Hale G. et al. (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62, 873-882
116Nückel H., Frey U.H., Röth A., Dührsen U. and Siffert W. (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. European Journal of Pharmacology 514, 217-224
117Hale G. et al. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2, 1394-1399
118Osterborg A. et al. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 15, 1567-1574
119Keating M.J. et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554-3561
120Rai K.R. et al. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology 20, 3891-3897
121Ferrajoli A. et al. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98, 773-778
122Cortelezzi A. et al. (2005) A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 90, 410-412
123Lundin J. et al. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768-773
124Hillmen P. et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 25, 5616-5623
125Elter T. et al. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology 23, 7024-7031
126Kennedy B. et al. (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99, 2245-2247
127Wierda W.G. et al. (2008) CFAR, an active frontline regimen for high-risk patients with CLL including those with del 17p. Blood 112, 2095 [Abstract]
128O'Brien S.M. et al. (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98, 2657-2663
129Moreton P. et al. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 23, 2971-2979
130Lozanski G. et al. (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103, 3278-3281
131Morris J.C., Waldmann T.A. and Janik J.E. (2008) Receptor-directed therapy of T-cell leukemias and lymphomas. Journal of Immunotoxicology 5, 235-248
132Pawson R. et al. (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Journal of Clinical Oncology 15, 2667-2672
133Dearden C.E. et al. (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98, 1721-1726
134Keating M.J. et al. (2002) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Journal of Clinical Oncology 20, 205-213
135Lundin J. et al. (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101, 4267-4272
136Kennedy G.A. et al. (2003) Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. European Journal of Haematology 71, 250-256
137Alinari L., Geskin L., Grady T., Baiocchi R.A., Bechtel M.A. and Porcu P. (2008) Subcutaneous alemtuzumab for Sézary syndrome in the very elderly Leukemia Research 32, 1299-1303
138Zhang Z., Zhang M., Goldman C.K., Ravetch J.V. and Waldmann T.A. (2003) Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Research 63, 6453-6457
139Mone A. et al. (2005) Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFNalpha-refractory adult T-cell leukemia. Blood 106, 3380-3382
140Ravandi F. and Faderl S. (2006) Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leukemia Research 30, 103-105
141Sharma S. et al. (2008) Alemtuzumab (Campath-1H) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Blood 112, 2010 [Abstract]
142Janik J.E. et al. (2005) A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies. Blood 106, 3348 [Abstract]
143Non-Hodgkin's Lymphoma Classification Project. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89, 3909-3918
144Armitage J.O. and Weisenburger D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. Journal of Clinical Oncology 16, 2780-2795
145Groves F.D., Linet M.S., Travis L.B. and Devesa S.S. (2000) Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. Journal of the National Cancer Institute 92, 1240-1251
146Gisselbrecht C. et al. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92, 76-82
147Moingeon P. et al. (1989) The structural biology of CD2. Immunological Reviews 111, 111-144
148Moingeon P.E. et al. (1991) Complementary roles for CD2 and LFA-1 adhesion pathways during T-cell activation. European Journal of Immunology 21, 605-610
149van der Merwe P.A. and Davis S.J. (2003) Molecular interactions mediating T cell antigen recognition. Annual Review of Immunology 21, 659-684
150Xu Y. et al. (2004) The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. Clinical and Experimental Immunology 138, 476-483
151Shaffer J. et al. (2007) Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Experimental Hematology 35, 1140-1152
152Zhang Z., Zhang M., Ravetch J.V., Goldman C. and Waldmann T.A. (2003) Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102, 284-288
153O'Mahony D. et al. (2007) A Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. AIDS Research and Human Retroviruses 23, 598 [Abstract]
154O'Mahony D. et al. (2009) EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clinical Cancer Research 15, 2514-2522
155Garcia K.C. and Adams E.J. (2005) How the T-cell receptor sees antigen- A structural view. Cell 122, 333-336
156Kirk A.D. (2006) Induction immunosuppression. Transplantation 82, 593-602
157Knop S. et al. (2007) Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: A randomized multi-center trial by the EBMT Chronic Leukemia Working Party. Leukemia 21, 1830-1833
158Chatenoud L. (2003) CD3-specific antibody-induced active tolerance: From bench to bedside. Nature Reviews Immunology 3, 123-132
159Gramatzki M. et al. (1995) Therapy with OKT3 monoclonal antibody in refractory T-cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia 9, 382-390
160Leahy D.J. (1995) A structural view of CD4 and CD8. FASEB Journal 9, 17-25
161Knox S.J. et al. (1991) Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 77, 20-30
162Knox S. et al. (1996) Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87, 893-899
163Kim Y.H. et al. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109, 4655-4662
164Rider D.A. et al. (2007) A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Research 67, 9945-9953
165Lozano F. et al. (2000) CD5 signal transduction: Positive or negative modulation of antigen receptor signaling. Critical Reviews in Immunology 20, 347-358
166Miller R.A., Oseroff A.R., Stratte P.T. and Levy R. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62, 988-995
167Dillman R.O., Shawler D.L., Dillman J.B. and Royston I. (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. Journal of Clinical Oncology 2, 881-891
168Foss F.M. et al. (1998) Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clinical Cancer Research 4, 2691-2700
169Robb R.J., Munck A. and Smith K.A. (1982) T-cell growth factor receptors. Journal of Experimental Medicine 154, 1455-1474
170Morris J.C. and Waldmann T.A. (2000) Advances in interleukin 2 receptor targeted treatment. Annals of the Rheumatic Diseases 59 (Suppl. 1), 109-114
171Waldmann T.A. (1986) The structure, function, and expression of interleukin-2 receptors on normal and malignant T-cells. Science 232, 727-732
172Uchiyama T., Broder S. and Waldmann T.A. (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. Journal of Immunology 126, 1393-1397
173Uchiyama T., Nelson D.L., Fleisher T.A. and Waldmann T.A. (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. II. Expression of Tac antigen on activated cytotoxic killer T-cells, suppressor cells, and on one of two types of helper T-cells. Journal of Immunology 126, 1398-1403
174Queen C. et al. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proceedings of the National Academy of Sciences of the United States of America 86, 10029-10033
175Zhang M. et al. (2004) Activating Fc receptors are required for anti-tumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Research 64, 5825-5829
176Nashan B., Light S., Hardie I.R., Lin A. and Johnson J.R. (1999) Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67, 110-115
177Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D. and Gallo R.C. (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 77, 7415-7419
178Matutes E. (2007) Adult T-cell leukaemia/lymphoma. Journal of Clinical Pathology 60, 1373-1377
179Tendler C.L. et al. (1990) Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: Pathogenic implications and a rationale for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 87, 5218-5222
180Waldmann T.A. et al. (1993) The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82, 1701-1712
181Waldmann T.A. et al. (1995) Radioimmunotherapy of interleukin-2Ra-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86, 4063-4075
182Morris J.C. et al. (2003) A Phase I trial of humanized anti-Tac (daclizumab) for the treatment of human T-cell lymphotrophic virus type-1-associated leukemia/lymphoma. Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 22, 695 [Abstract]
183Kreitman R.J., Bailon P., Chaudhary V.K., FitzGerald D.J. and Pastan I. (1994) Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 83, 426-434
184Kreitman R.J. et al. (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Journal of Clinical Oncology 18, 1622-1636
185Tsudo M., Kozak R.W., Goldman C.K. and Waldmann T.A. (1986) Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proceedings of the National Academy of Sciences of the United States of America 83, 9694-9698
186Tsudo M., Kitamura F. and Miyasaka M. (1989) Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America 86, 1982-1986
187Shanmugham L.N. et al. (2006) IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. Journal of Experimental and Clinical Cancer Research 25, 529-536
188Waldmann T.A. (2006) The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nature Reviews Immunology 6, 595-601
189Kanegane H. and Tosato G. (1996) Activation of naive and memory T-cells by interleukin-15. Blood 88, 230-235
190Guex-Crosier Y. et al. (1997) Humanized antibodies against the alpha-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. Journal of Immunology 158, 452-458
191Alileche A., Goldman C.K. and Waldmann T.A. (2001) Differential effects of IL-2 and IL-15 on expression of IL-2 receptor-α. Biochemical and Biophysical Research Communications 285, 1302-1308
192Giri J.G., Anderson D.M., Kumaki S., Park L.S., Grabstein K.H. and Cosman D. (1995) IL-15, a novel T-cell growth factor that shares activities and receptor components with IL-2. Journal of Leukocyte Biology 57, 763-766
193Morris J.C. et al. (2006) Preclinical and phase I clinical trial of blockade of IL-15 using Mik-β-1 monoclonal antibody in T-cell large granular lymphocyte leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 401-406
Waldmann T.A. and Morris J.C. (2006) Development of antibodies and chimeric molecules for cancer immunotherapy, In Allison J.P. and Dranoff G. (eds.) Advances in Immunology: Cancer Immunotherapy 90, 83-131. Elsevier Academic Press.
Morris J.C., Waldmann T.A. and Janik J.E. (2008) Receptor-directed therapy of T-cell leukemias and lymphomas. Journal of Immunotoxicology 5, 235-248.
Kreitman R.J. (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23, 1-13.
Migkou M., Dimopoulos M.A., Gavriatopoulou M. and Terpos E. (2009) Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opinion on Biological Therapy 9, 207-220.

Up-to-date treatment news on leukemia and lymphoma diagnosis and treatment is available at:

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 12
Total number of PDF views: 14 *
Loading metrics...

Abstract views

Total abstract views: 173 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st November 2017. This data will be updated every 24 hours.